Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02864199 · ClinicalTrials.gov registry record · Phase 4

A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment

A Phase 4 study of Hepatitis C, Chronic, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 4
Development phase
63
Enrollment target
17
Study locations

NCT02864199: Completed Phase 4 study of Hepatitis C, Chronic, sponsored by Hoffmann-La Roche.

NCT02864199 is a Phase 4 study of Hepatitis C, Chronic that has completed, run by Hoffmann-La Roche. The registered enrollment target is 63 participants, below the 374-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (83% lower). The trial reports 17 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02864199, a Phase 4 study of Hepatitis C, Chronic, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 4
Development phase
63 participants
Enrollment target
17
Study locations

Study Summary

This study will evaluate the pharmacokinetics (area under the curve \[AUC\], maximum concentration \[Cmax\], and other parameters) and tolerability of peginterferon alfa-2a and ribavirin combination therapy following single and multiple doses in participants with CHC infection and moderate to severe renal impairment or end-stage renal disease (ESRD) receiving hemodialysis. The anticipated time on study treatment is up to 48 weeks, and the target sample size is 48 individuals.

Conditions Studied

Hepatitis C, Chronic

Interventions

  • DRUG Ribavirin
  • DRUG Peginterferon alfa-2a

Study Locations (17)

Other

  • - São Paulo
  • - Marseille
  • - Christchurch
  • - Riccarton, Christchurch
  • - Huddinge

Missouri

  • - Kansas City
  • - St Louis

New York

  • - New York
  • - Syracuse

Texas

  • - Dallas
  • - Galveston

Alabama

  • - Birmingham

Kansas

  • - Kansas City

Louisiana

  • - New Orleans

Ohio

  • - Cleveland

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2004-02
Est. Completion 2007-09
Phase Phase 4
Hoffmann-La Roche

909 total trials

What the finished NCT02864199 record still lists

NCT02864199 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 374-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Hepatitis C, Chronic appearing as the primary indexed condition, and to 2 interventions - of which Ribavirin is the first listed.

NCT02864199 lists 17 locations in 10 states (Other, Missouri, New York).

Frequently Asked Questions

What is clinical trial NCT02864199 about?

NCT02864199 is a clinical study titled "A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment". This study will evaluate the pharmacokinetics (area under the curve \[AUC\], maximum concentration \[Cmax\], and other parameters) and tolerability of peginterferon alfa-2a and ribavirin combination therapy following single and multiple doses in participants with CHC infection and moderate to severe...

What is the current status of trial NCT02864199?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 63 participants. The study started on 2004-02. Estimated completion is 2007-09.

What conditions does trial NCT02864199 study?

This clinical trial studies the following conditions: Hepatitis C, Chronic.

What interventions are being tested in trial NCT02864199?

The interventions under investigation include: Ribavirin (DRUG), Peginterferon alfa-2a (DRUG).

Who is sponsoring clinical trial NCT02864199?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02864199 being conducted?

This trial has 17 study locations across Alabama, Kansas, Louisiana, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C, Chronic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02864199's enrollment target sits among peer trials

63 22nd of 26 higher than 5 of 26 other Hepatitis C, Chronic trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hepatitis C, Chronic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03383575 · 63 participants · Phase 2

    Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

  • NCT04870944 · 63 participants · Phase 1

    CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • NCT05031897 · 63 participants · Phase 2

    Two Step Haplo With Radiation Conditioning

  • NCT05312671 · 63 participants · Phase 2

    Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02864199, the US trial registry maintained by the National Library of Medicine. NCT02864199 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.